Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of ...

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, ...

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment ...

Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 ...

Carrillo, MD, discusses results of a study which sought to assess the association between thymectomy and incidence of renal ...

C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated ...

Although immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast ...

During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on ...

Recently published guidelines from the FDA aim to expand eligibility criteria in clinical trials with recommendations for ...

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant ...

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of ...

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.